Divergent HIV-1 Restriction Phenotypes of IFITMs Expressed in Target Cells and Incorporated into Virions
Biomolecules · 18.03.2026 · 16 (3) · 459
DOI: 10.3390/biom16030459 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, online erschienen am 18.03.2026. Verfasst von Smita Verma und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA 30322, USA. Hauptthemen laut MEDLINE: HIV-1, Virion, Membrane Proteins, RNA-Binding Proteins. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ANRS|MIE, National Institute of Allergy and Infectious Diseases, NIAID NIH HHS.
Abstract (Originalsprache)
Interferon-induced transmembrane proteins (IFITMs) are broad-spectrum antiviral factors that restrict the entry of many enveloped viruses, including HIV-1, by modifying host membrane properties and trapping fusion at the hemifusion stage. Beyond blocking entry in target cells, IFITMs also reduce the infectivity of virions produced from IFITM-expressing cells, a phenomenon termed “negative imprinting”. Conserved motifs, such as the amphipathic helix and oligomerization motifs, have been reported to be essential for IFITM-mediated protection of target cells from viral infection. Yet, the impact of IFITM incorporation on progeny virion infectivity remains poorly defined. Here, we show that IFITM3 mutants defective in target cell protection activity still markedly impair HIV-1 fusion/infection upon incorporating into virions, without affecting viral maturation or Env incorporation. Immunofluorescence studies suggest mislocalization of the IFITM3 mutants as the reason for the lack of antiviral activity in target cells. Testing the antiviral activity of chimeras between antiviral and non-antiviral IFITM orthologs failed to clearly identify a domain responsible for reduction of HIV-1 infectivity, suggesting that multiple domains may be required for negative imprinting. Interestingly, co-incorporation of non-antiviral dog IFITM1 with human IFITM3 did not interfere with IFITM3’s negative imprinting activity, despite forming mixed hetero-oligomers. This finding implies a dominant, oligomerization-independent antiviral phenotype of IFITM3 in virions. Our findings suggest that IFITMs may protect target cells and negatively imprint progeny virions through distinct mechanisms, underscoring the need to further characterize the molecular basis for the reduced fusion competence of IFITM-containing HIV-1 particles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA 30322, USA.
- Department of Physiology and Biophysics, Rush University, Chicago, IL 60612, USA.
- Centre International de Recherche en Infectiologie (CIRI), Université de Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Nationale Supérieure de Lyon, 69007 Lyon, France.
- Children's Healthcare of Atlanta, Atlanta, GA 30322, USA.
ORCID-Profile: Smita Verma, Gregory B Melikyan
Förderung
- ANRS|MIE
- National Institute of Allergy and Infectious Diseases
- NIAID NIH HHS
- NIH/NIAID
Zitieren
APA
Verma, S., Prikryl, D., Marin, M., Markosyan, R. M., Cimarelli, A., & Melikyan, G. B. (2026). Divergent HIV-1 Restriction Phenotypes of IFITMs Expressed in Target Cells and Incorporated into Virions. Biomolecules, 16(3), 459. https://doi.org/10.3390/biom16030459
Vancouver
Verma S, Prikryl D, Marin M, Markosyan RM, Cimarelli A, Melikyan GB. Divergent HIV-1 Restriction Phenotypes of IFITMs Expressed in Target Cells and Incorporated into Virions. Biomolecules. 2026;16(3):459. doi:10.3390/biom16030459
BibTeX
@article{Verma2026,
author = {Verma, Smita and Prikryl, David and Marin, Mariana and Markosyan, Ruben M and Cimarelli, Andrea and Melikyan, Gregory B},
title = {Divergent HIV-1 Restriction Phenotypes of IFITMs Expressed in Target Cells and Incorporated into Virions},
journal = {Biomolecules},
year = {2026},
volume = {16},
number = {3},
pages = {459},
doi = {10.3390/biom16030459}
}
EUVIMED